Skip to main content
Fig. 3 | Allergy, Asthma & Clinical Immunology

Fig. 3

From: Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom

Fig. 3

Proportion of the UK and non-UK IOS patients hospitalized at baseline (prior to IOS entry) and during IOS observation. For the UK and non-UK patients, respectively, n = 68 and n = 367 for the period before IOS entry and n = 52 and n = 399 for the IOS follow-up period. BL baseline (12 months prior to IOS entry), FU follow-up, IOS Icatibant Outcome Survey. aNon-UK countries are Austria, Brazil, Denmark, France, Germany, Greece, Israel, Italy, Spain and Sweden

Back to article page